The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale

Harrington, Robert; Van de Werf, Frans; Armstrong, Paul; Aylward, Phil; Veltri, Enrico; Mahaffey, Kenneth; Moliterno, David; Strony, John; Wallentin, Lars; White, Harvey; Diaz, Rafael; Huber, Kurt; Nicolau, Jose; Carlos Prieto, Juan; Isaza, Daniel; Widimsky, Petr; Grande, Peer; Nieminen, Markku; Montalescot, Gilles; Bode, Christoph; Wong, Lawrence; Ofner, Peter; Lewis, Basil; Ambrosio, Giuseppe; Valgimigli, Marco; Ogawa, Hisao; Yamaguchi, Jun-ichi; Jukema, J.; Cornel, Jan; Nordrehaug, Jan; Ruzyllo, Witold; Providencia, Luis; Tan, Huay-Cheem; Dalby, Anthony; Seung-Jung, Park; Betriu, Amadeo; Cequier, Angel; Held, Claes; Pfisterer, Mathias; Ming-Fong, Chen; Timurkaynak, Timur; Storey, Robert; Chen, Edmond; Hudson, Michael; Lincoff, A.; Morrow, David; Tricoci, Pierluigi; Whellan, David

doi:10.1016/j.ahj.2009.07.001

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale

Atıf İçin Kopyala

Harrington R. A., Van de Werf F., Armstrong P. W., Aylward P., Veltri E., Mahaffey K. W., ...Daha Fazla

AMERICAN HEART JOURNAL, cilt.158, sa.3, ss.327-338, 2009 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 158 Sayı: 3
Basım Tarihi: 2009
Doi Numarası: 10.1016/j.ahj.2009.07.001
Dergi Adı: AMERICAN HEART JOURNAL
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.327-338
Gazi Üniversitesi Adresli: Evet

Özet

Background The protease-activated receptor 1 (PAR-1), the main platelet receptor for thrombin, represents a novel target for treatment of arterial thrombosis, and SCH 530348 is an orally active, selective, competitive PAR-1 antagonist. We designed TRA.CER to evaluate the efficacy and safety of SCH 530348 compared with placebo in addition to standard of care in patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) and high-risk features.